Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled pirfenidone in prior Avalyn antifibrotic study participants
NL-OMON60589Phase 2Recruiting
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Avalyn Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events, Incidence of adverse events of special interest and 4 more. Started Jul 2025; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON60589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60589.